Drug intelligence / Profile preview

MG01

Development stage
Unknown
Lead developer
Inmunotek
Modality
Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration
Subcutaneous
01

Overview

MG01 is an investigational **subcutaneous allergen immunotherapy** developed by Inmunotek for grass-pollen allergy. It is a purified grass-pollen allergen extract chemically polymerized with glutaraldehyde to form an allergoid, intended to reduce allergenicity while preserving immunogenicity. The grass mixture has been described as including *Phleum pratense*, *Holcus lanatus*, *Poa pratensis*, *Festuca pratensis*, *Lolium perenne*, and *Dactylis glomerata*. MG01 is being evaluated alone and in mixtures with other allergen extracts for allergic rhinitis, allergic rhinoconjunctivitis, and mild-to-moderate allergic asthma.

Other names
MG-01MG01MG 016 Grass Mix
02

Targets

Grass pollen allergen-specific immunoglobulin G (IgG) and B-cell receptor (BCR)IgE (Immunoglobulin E)MRC1 (Mannose Receptor C-type 1)

Beyond the preview

Go deeper on MG01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MG01.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call